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Abstract:  For the first time in decades, patients with difficult-to-treat cancers such as melanoma are 23 
being offered a glimpse of hope in the form of immunotherapies. By targeting factors that foster the 24 
development and maintenance of an immunosuppressive microenvironment within tumors, these 25 
therapies release the breaks on the host’s own immune system; allowing cure of disease. Indeed, 26 
phase III clinical trials have revealed that therapies such as ipilimumab and pembrolizumab which 27 
target the CTLA4 and PD-1 immune checkpoints, respectively, have raised the three-year survival 28 
of patients with melanoma to ~70%, and overall survival (>5 years) to ~30%. Despite this 29 
unprecedented efficacy, many patients fail to respond, and more concerning, some patients who 30 
demonstrate encouraging initial responses to immunotherapy, can acquire resistance over time. 31 
There is now an urgent need to identify mechanisms of resistance, to predict outcome and to 32 
identify targets for combination therapy. Here, with the aim of guiding future combination trials that 33 
target specific resistance mechanisms to immunotherapies, we have summarised and discussed the 34 
current understanding of mechanisms promoting resistance to anti-PD1/PDL1 therapies, and how 35 
combination strategies which target these pathways might yield better outcomes for patients.  36 
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Introduction 40 
Cancer immunotherapies that target the immunosuppressive checkpoint receptors cytotoxic 41 
T-lymphocyte-associated protein 4 (CTLA4) or programmed death 1 (PD1) and its ligand, 42 
programmed death 1 ligand (PDL1) have changed the landscape of anti-cancer immunotherapy [1]. 43 
In particular, checkpoint inhibitors targeting PD1 and PDL1 have demonstrated unprecedented 44 
clinical efficacy in more than 15 cancer types including melanoma, non-small cell lung cancer 45 
(NSCLC), renal cell carcinoma (RCC), bladder carcinoma and Hodgkin’s lymphoma [2]. This 46 
success prompted FDA approval of two anti-PD1 monoclonal antibody (mAb) therapies, nivolumab 47 
(Opdivo®) and pembrolizumab (Keytruda®) for the treatment of NSLC, metastatic melanoma, and 48 
renal cell carcinoma, or NSLC, and advanced melanoma, respectively. Nevertheless, primary 49 
resistance to anti-PD1 therapies is common, affecting up to 60% of patients in some cancer types 50 
[3]. Furthermore, it is now becoming apparent that encouraging initial responses observed amongst 51 
some patients can be undone by their development of acquired resistance to anti-PD1 therapies 52 
(referred to throughout as acquired resistance) leading to disease relapse [4]. A substantial effort is 53 
currently underway to fully elucidate the mechanisms by which anti-PD1/PDL1 therapies exert their 54 
efficacy, to understand mechanisms of resistance present within some patients that limit their 55 
activity, and to develop a priori combination therapeutic approaches to sensitise resistant patients. 56 
The mechanisms of action and clinical efficacy of anti-PD1 therapies have been reviewed 57 
extensively elsewhere [5-7]. By contrast, this review will discuss the current understanding of 58 
cellular and molecular pathways that contribute to the development of anti-PD1/PDL1 resistance. 59 
This will be done by briefly discussing the current understanding of tumor-induced immune 60 
suppression, the effect that anti-PD1 therapy can have upon anti-tumor immune responses, and the 61 
particular phenotypes and pathways that have been identified to contribute to resistance. Finally, the 62 
potential efficacy of specific combination therapeutic approaches for improving sensitivity to anti-63 
PD1/PDL1 therapies will be discussed.  64 
 65 
  
PD1 within the tumor microenvironment  66 
It is now appreciated that tumors usually contain specialized immunosuppressive 67 
microenvironments that enable disease development and progression. These tumor 68 
microenvironments are dynamic and regulated by complex interactions between tumor tissue and 69 
tumor-associated immune and non-immune cells [8]. In recent years, a number of 70 
immunoregulatory pathways have been shown to be essential for maintaining immune suppression 71 
and preventing the release of host-generated anti-tumor immune responses. These pathways, known 72 
as immune checkpoints, which function under physiological conditions to modulate the duration 73 
and amplitude of immune responses, are often hijacked by tumors [9]. The checkpoint regulated by 74 
interactions between the PD1 receptor and its primary ligand, PDL1, appears to be of extreme 75 
importance within a variety of tumors. Under physiological conditions, the engagement of PD1 76 
expressed by activated CD8+ T-cells with PDL1 functions to limit collateral damage. Following 77 
engagement, PD1 transmits inhibitory signals that abrogate T-cell receptor (TCR)-mediated 78 
activating signals; preventing further antigen-mediated T-cell activation. Not only does this 79 
pathway limit T-cell responsiveness,  it can also lead to the development of an exhausted T-cell 80 
phenotype; characterized  by a hierarchical loss of proliferation and cytolytic activity, followed by 81 
defects in cytokine production, and eventually deletion [10].  82 
Many tumors express PD1 ligands which can engage with PD1 expressed by tumor antigen-83 
specific T-cells patrolling the tumor microenvironment. Within a minority of tumors, PDL1 has 84 
been reported to be expressed in a constitutive fashion driven by oncogenic (e.g. EGFR and ALK, 85 
within NSCLC) or tumor suppressor mutations (PTEN within some glioblastomas) [11-13]. 86 
Alternatively, most tumors express PDL1 in a reactive and adaptive fashion in response to 87 
inflammatory cytokines such as type I and II interferons (IFNs, primarily IFNγ) and tumor necrosis 88 
factor α (TNFα) to prevent immune-mediated assault; a phenomenon now defined as adaptive 89 
immune resistance [6, 9]. Of note, some human liver and ovarian tumors have been shown to up-90 
regulate the alternative PD1 ligand, programmed death ligand 2 (PDL2), however, these comprise a 91 
  
minority of cases, and PDL1 appears to be the dominant PD1 ligand within human cancers [14]. 92 
Expression of PD1 by effector lymphocytes, and PDL1 by tumor cells and tumor-associated 93 
immune cells, can be indicative of an ongoing immune response. Following the manifestation of 94 
clinically apparent disease, however, the steady-state function of tumor-infiltrating lymphocytes 95 
(TILs) is clearly insufficient to control disease progression [15]. Therapeutic mAbs targeting either 96 
PD1 or PDL1 block  ligand/receptor interactions to release T-cells from their exhausted phenotype, 97 
and allow for reinvigoration of tumor antigen-specific immunity [9]. 98 
Clinical data for anti-PD1 therapy  99 
As previously mentioned, while highly effective, anti-PD1/PDL1 therapies engender little to 100 
no benefit for many patients, and patients can be stratified as being sensitive, or as displaying either 101 
primary or acquired resistance (Figure 1)  [16, 17]. For example, the posterchild for success in anti-102 
PD1 therapy, and also the example for which clinical data are most mature, is melanoma. Treatment 103 
with anti-PD1 immunotherapy and BRAF-molecularly targeted therapy has revolutionised the 104 
treatment of advanced-stage disease (unresectable stage III or stage IV); the 1 year overall survival 105 
(OS) for such patients was 25-30% in 2009 [18], and exceeds 70% for patients treated with single 106 
agent anti-PD1 therapies or targeted therapies [19-23].  Phase 3 trials of either of the PD1 inhibitors 107 
nivolumab or pembrolizumab, demonstrated a significant improvement in outcomes for patients 108 
with advanced melanoma compared with ipilimumab.  109 
In the phase 3 study Keynote 006 [20], the response rate for two different dosing schedules 110 
of pembrolizumab was 37% (2-weekly pembrolizumab) and 36% (3-weekly pembrolizumab, the 111 
currently approved dosing interval), whereas the response rate for ipilimumab was 13%.  Moreover, 112 
the 1- and 2-year PFS was 38% and 28% for the pembrolizumab cohort treated every 3 weeks, and 113 
19% and 14% for ipilimumab (HR=0.61, p<0.00001). Pembrolizumab also significantly improved 114 
the OS, with a 1- and 2-year OS of 68% and 55% (3 weekly cohort) compared with 59% and 43% 115 
for ipilimumab (HR=0.68, p<0.001), despite subsequent anti-PD1/PDL1 based therapy in 31% of 116 
  
all those who received ipilumumab. Similarly, in the three-arm phase 3 study Checkmate 067 [22, 117 
23], the response rate for ipilimumab, nivolumab and the combination was 19%, 44%, and 58% 118 
respectively, and the 1-year progression-free survival was 18%, 42% and 49% (HR=0.55 119 
[nivolumab versus ipilimumab], p<0.00001; HR=0.42 [nivolumab+ipilimumab vs ipilimumab], 120 
p<0.00001). Caution should be taken in the interpretation of such data as the latter trial was not 121 
powered to allow for comparisons between responses to nivolumab versus nivolumab in 122 
combination with ipilimumab. 123 
Long-term survival data for these therapies are now emerging, and in the phase 1 study of 124 
pembrolizumab in 655 patients [24], the 3-year survival was 40% for the total population and 45% 125 
for patients who received pembrolizumab in the first line setting. The RECIST response in the 126 
overall population was 33%, yet only 57% of these responders remained in response at 3 years; the 127 
remainder developed acquired resistance. By contrast, 61 patients who had a CR ceased therapy, 128 
and with a median follow up of 10 months, 59 (98%) remained in CR [24] . Similarly, in a small 129 
phase 2 study of nivolumab combined with ipilimumab versus ipilimumab alone, the combination 130 
resulted in a 1- and 2-year OS of 73% and 64% respectively [25, 26] and in the 23 responders who 131 
ceased due to toxicity, 17 (74%) remained in response after a minimum follow up of two years. 132 
Resistance to PD1/PDL1 checkpoint inhibition  133 
When considering why some patients are resistant to anti-PD1/PDL1 therapies, it is likely 134 
that understanding their mechanisms of action is important. Sensitivity to anti-PD1 therapy requires 135 
the existence of tumor antigen-specific T-cells within tumor tissue, functionally suppressed by 136 
PD1/PDL1 interactions [27]. By limiting the interaction of PD1 with PDL1, anti-PD1/PDL1 137 
therapies can promote reinvigoration of anti-tumor immunity [28]. As a consequence, such T-cells 138 
should be able to mount effector responses with the same vigour as newly-generated effector T-139 
cells; as cytokine production, proliferative capacity, and memory development appear to be equally 140 
restored [29]. By implication, the mechanisms underlying the development of either primary or 141 
  
acquired resistance to anti-PD1/PDL1 therapies must function to counteract the activity of tumor-142 
specific T-cells prior to, or in response to therapy. To that end, we propose that mechanisms 143 
promoting either primary or acquired resistance are largely conserved, and that they must affect 144 
either, (i) tumor immunogenicity, (ii) antigen presentation and generation of effector T-cells, (iii) 145 
the encounter of antigen and PDL1 by tumor-specific T-cells, (iv) the activity and efficacy of 146 
tumor-specific immune responses, (v) or the induction of immunological memory (Figure 2). The 147 
remainder of this review will explore how these pathways can be disrupted, by drawing upon recent 148 
data derived from both pre-clinical mouse models and clinical trials, which have elucidated some 149 
mechanisms of resistance to anti-PD1/PDL1 therapies.   150 
Tumor immunogenicity  151 
The efficacy of anti-PD1 therapy is dependent upon the existence of tumor antigen-specific 152 
T-cells within tumor tissue. This requires that tumors express antigens that differentiate themselves 153 
from their non-transformed counterparts. Failing this, poor or absent anti-tumor immunity likely 154 
renders anti-PD1 therapy ineffective. Such antigens must theoretically be derived from non-mutated 155 
proteins to which T-cell tolerance is incomplete, viral antigens where malignant transformation is 156 
promoted by viral infection, or non-synonymous mutations that give rise to novel protein products 157 
known as neoantigens. The in-depth profiling of human cancer mutations by deep sequencing has 158 
enabled recognition that non-synonymous mutations which generate tumor-specific neoantigens are 159 
of extreme importance in directing tumor-specific immunity [30-33]. Importantly, the pool of 160 
mutations capable of producing immunogenic neoantigens is limited by their requirement to be non-161 
synonymous and present within exomes, to be efficiently cross-presented by antigen presenting 162 
cells (APCs), and unaffected by the immunodominance of other antigens. This implies that poorly 163 
immunogenic tumors should be largely resistant to anti-PD1 therapy. This has been recently borne-164 
out by the observation that tumor neoantigen burden strongly correlates with immunogenicity and 165 
with sensitivity to anti-PD1 therapy [34]. Human melanoma, RCC, and NSCLC are highly 166 
immunogenic, boasting mutational loads in the range of 5 to 10 somatic mutations per mega-base of 167 
  
DNA [3, 32]. Accordingly, these are amongst the most sensitive of tumors to anti-PD1 therapy. By 168 
contrast, poorly immunogenic tumors such as those of the pancreas and prostate which tend to have 169 
between 0.1 and 1 somatic mutation per mega-base of DNA are largely resistant to anti-PD1 170 
therapy [32, 35]. Additionally, neoantigen-enriched tumors have been shown to contain a greater 171 
abundance of CD8+ T-cells and elevated levels of granzyme A (GZMA) and perforin (PRF1) 172 
mRNA; consistent with elevated T-cell-mediated cytolytic activity [36]. Although likely affected by 173 
a variety of tumor cell-intrinsic factors, the mutational burden, and in turn, the immunogenicity of 174 
individual tumors might be influenced during development by the speed at which 175 
immunosuppressive pathways are adopted. For example, during early stages of tumor development, 176 
a large proportion of neoantigens can be edited-out by a process of immunoediting [37]. The 177 
induction of PDL1 at an earlier rather than later stage of tumor development might lead to the 178 
outgrowth of tumors with greater immunogenicity. The timing of PDL1 induction within different 179 
tumors might be influenced by the particular tissue from which the tumor arises and the relevance 180 
of the PD1/PDL1 checkpoint therein. As such, the paucity of PDL1 expression within the prostate 181 
might explain a lack of its expression within tumors arising there and in turn, their common primary 182 
resistance to anti-PD1 therapy [35]. Amongst patients who initially respond to anti-PD1 therapy, the 183 
reinvigoration to anti-tumor immunity might lead to selection of tumor clones with the capacity to 184 
subvert T-cell responses. This could occur via a number of pathways including antigen loss, down-185 
regulation of class I MHC via β2M mutation [38, 39], mutations that affect signalling pathway 186 
molecules within the JAK-STAT pathway, necessary for responsiveness to IFNs [40, 41], or even 187 
outgrowth of tumor cells which induce alternative immunosuppressive pathways. Therefore, 188 
mutational burden and immunogenicity may be relevant as either a primary or acquired resistance 189 
mechanism. 190 
 191 
 192 
  
Antigen presentation and effector T-cell activation  193 
The priming and activation of effector T-cells with specificity for tumor antigen is carried 194 
out by APCs such as dendritic cells (DCs). Constitutively patrolling the blood, peripheral tissues, 195 
lymph, and secondary lymphoid organs, DCs sample the extracellular environment and phagocytose 196 
self- and non-self-antigens [42]. In the presence of activating signals, DCs undergo maturation, 197 
which amongst other things, increases the efficiency of antigen processing, motility, and expression 198 
of costimulatory machinery necessary for T-cell activation. Maturation is, however, insufficient for 199 
T-cell activation; DCs must migrate to secondary lymphoid organs and present MHC to naïve T-200 
cells [42]. Engagement between a DC and T-cell expressing cognate TCR, with appropriate co-201 
stimulation can lead to T-cell activation [43]. Unsurprisingly, mechanisms have been identified that 202 
perturb antigen presentation and T-cell activation resulting in resistance to anti-PD1 therapy. 203 
Recently, Spranger et al. identified that mutations in human melanomas which increase the stability 204 
and signalling of β-catenin, can reduce expression of chemokine C-C motif ligand 4 (CCL4); 205 
important for DC migration [44]. Reduced CCL4 was associated with a general absence of TILs, 206 
culminating in resistance to anti-PD1 therapy. Other studies have also linked the inefficient 207 
infiltration of DCs into the tumor microenvironment with resistance to anti-PD1 therapy [44]. An 208 
recent study showed that mouse models lacking flora of the Bifidobacterium genus within their gut 209 
microbiome displayed a significant reduction of intratumoral DCs and extremely poor responses to 210 
anti-PD1 therapy [45]. Similar findings have been reported for sensitivity to anti-CTLA4 therapy 211 
[46]. Unfortunately, the mechanisms influencing DC infiltration and immune activation in response 212 
to the gut microbiome have not been clarified.  213 
In addition to perturbing DC migration, some tumors have been demonstrated to disrupt DC 214 
maturation. The cytokine milieu present within some tumors has been demonstrated to affect DC 215 
maturation. Although commonly discussed in the context of cancer with respect to its pro-216 
angiogenic properties, vascular endothelial growth factor (VEGF) can also limit DC maturation. 217 
  
VEGF, a cytokine commonly produced by both tumor and associated immune cells, via stimulation 218 
of VEGF receptor 1 (VEGFR1), can suppress DC maturation via a nuclear factor kB (NFкB)-219 
dependent pathway [47]. Similar defects have been noted to occur in the presence of elevated 220 
tumor-derived transforming growth factor β (TGFβ) [48].  Additionally, IL-10 produced by 221 
immunosuppressive cell types such as regulatory T-cells (Tregs) within some tumors has been 222 
shown to affect DC maturation by reducing expression of class II MHC and costimulatory 223 
machinery [49]. As well as affecting egress of DCs harbouring tumor antigen from tumor tissue, 224 
cytokines such as VEGF and IL-10 can affect antigen presentation and T-cell activation. While 225 
immature DCs may still present antigen, defective co-stimulation can render them tolerogenic [38]. 226 
Although speculative, tumor microenvironments in which VEGF, TGFβ or IL-10 are elevated, 227 
might also promote resistance to anti-PD1 therapies by preventing activation of tumor antigen-228 
specific T-cells. Selection of tumor cells capable of subverting physiological antigen presentation 229 
and T-cell activation likely promotes their development by enhancing survival [50].  230 
PD1/PDL1 interactions 231 
T-cell activation requires the direct apposition of antigen-specific T-cells with cells 232 
displaying cognate antigen; a phenomenon that also allows for ligation of PD1 expressed by T-cells 233 
with PDL1 expressed within the tumor microenvironment [51]. By implication, tumor-intrinsic 234 
properties that prevent migration of tumor-specific T-cells or PD1 activity within tumor tissue, 235 
likely limit the efficacy of anti-PD1 therapy. The immune contexture, including the location, 236 
density, and type of cells within the tumor microenvironment has been assessed in a variety of 237 
cancer types and shown within melanoma to have relevance to the sensitivity of patients to anti-238 
PD1 therapy [52-54]. Generally, the presence of a lymphocyte-enriched inflammatory infiltrate 239 
within colorectal, ovarian, pancreatic, oesophageal, and NSCLC tumors has been associated with 240 
better outcomes, and in some cases, response to anti-PD1 therapy [52]. In melanoma, where 241 
investigations have been most extensive, the presence of TILs within the invasive margin, but not 242 
  
necessarily the tumor parenchyma was correlated with sensitivity to anti-PD1 therapy. Analyses of 243 
specific lymphocyte subsets present highlighted CD8+ but not necessarily CD4+ T-cells as being 244 
correlated with response [15, 53]. Unsurprisingly, the presence of suppressive cell types such as 245 
myeloid-derived suppressor cells (MDSCs) within tumor tissue in abundance, and higher ratios of 246 
Foxp3+ Tregs to CD8+ T-cells have been associated with resistance [55-57]. Further supporting the 247 
importance of lymphocyte subsets within tumor tissue, the presence of a cytotoxic gene signature 248 
associated with functional immune responses has been correlated with sensitivity [58]. The 249 
prognostic significance of these observations is clear, however, the mechanisms promoting 250 
differences in the infiltration of lymphocyte and myeloid cells between tumors is poorly understood. 251 
One reason for poor immune infiltration might be the absence of tumor-specific T-cells; as 252 
previously discussed, tumor development would likely benefit from poor immunogenicity or 253 
suppression of effective antigen presentation [44]. However, some resistant tumors do contain TILs 254 
[59]. For example, in human melanomas, weak in situ expansion of exhausted, tumor-associated 255 
CD8+T-cells has been shown to correlate with poor prognosis, even in patients with robust tumor 256 
invasion of lymphocytes [53]. In contrast, in human melanomas, co-localisation of PD1+TILs with 257 
PDL1+tumor cells has been strongly correlated with response to anti-PD1 therapy; supporting the 258 
currently accepted mechanism by which anti-PD1/PDL1 therapies exert their efficacy [15]. 259 
Interestingly, however, anti-PD1 therapeutic resistance mechanisms have been described that 260 
overcome the reinvigoration provided by anti-PD1 therapy to exhausted tumor-associated 261 
lymphocytes. While T-cell exhaustion is the phenomenon targeted by anti-PD1 therapy, it appears 262 
that when taken to extreme limits, it can promote resistance to anti-PD1 therapy (Figure 3).  263 
Severe exhaustion  264 
Chronic exposure to cognate antigen can trigger up-regulation of PD1 expression, and by 265 
interacting with its ligand, PD1 can induce T-cell exhaustion [10]. Importantly, in vitro techniques 266 
have revealed that the strength of PD1 signalling – determined by its relative expression level or 267 
  
ligand abundance – can define the severity of T-cell exhaustion [60]. A consequence of this is that 268 
relative PD1 expression level likely affects the sensitivity of exhausted T-cells to anti-PD1 therapy.  269 
The presence of PD1high, severely exhausted T-cells within some tumor microenvironments studied 270 
in mice, have been associated with resistance to anti-PD1 therapy. Unlike such populations, 271 
exhausted T-cells with either PD1low or PD1intermediate expression retain their capacity to be 272 
reinvigorated by anti-PD1 therapy [61]. It is therefore likely that potent reversal of exhaustion by 273 
therapeutic intervention might depend on the proportion of T-cells that display a PD1intermediate to 274 
PD1high phenotype prior to therapy [10]. The PD1high phenotype of tumor-associated CD8+ T-cells 275 
within resistant tumors was found to partially depend upon tumor-associated Tregs [59]. While the 276 
existence of tumor-associated PD1high CD8+ T-cells was associated with primary resistance to anti-277 
PD1 therapy, it is possible that the development of severe T-cell exhaustion could lead to the 278 
development of acquired resistance. Although speculative, the compensatory induction of Tregs 279 
into tumor tissue following the anti-PD1-mediated release of adaptive immune resistance, could 280 
promote severe exhaustion of tumor-associated CD8+ T-cells and limit the efficacy of anti-PD1 281 
therapy.  282 
Co-expression of inhibitory receptors  283 
Associated with the severely exhausted phenotype of some T-cells is over-expression of 284 
multiple inhibitory receptors including, T-cell immunoglobulin mucin 3 (TIM3), CLTA4, 285 
lymphocyte activation gene 3 (LAG3) and B and T lymphocyte attenuator (BTLA), in addition to 286 
PD1. The immunosuppressive capacity of these receptors was initially defined in models of chronic 287 
infection such as lymphocytic choriomeningitis virus (LCMV) [62]. While there are similarities 288 
between antigen persistence in chronic infection and antigen persistence in cancers, it should be 289 
noted that it is not clear whether expression patterns and activity of such receptors behave in the 290 
same fashion under both conditions [10]. Recently, Thommen et al. identified that co-expression of 291 
PD1, TIM3, LAG3, CTLA4 and BTLA was associated with resistance to anti-PD1 therapy in 292 
  
NSLC [63]. CD8+ T-cells expressing the five receptors demonstrated severe defects in cytokine 293 
production, proliferation and migration. Interestingly, a spectrum of exhaustion was proposed 294 
whereby expression of PD1, TIM3, LAG3, and CTLA4 was associated with a mildly exhausted 295 
phenotype which was further exaggerated following expression of BTLA [63]. It is not known 296 
whether the primary resistance displayed by severely exhausted PD1high CD8+ T-cells is a product 297 
of compensatory signalling mediated through co-expressed inhibitory receptors, or whether elevated 298 
PD1 endows exhausted T-cells with an intrinsic defect in sensitivity to anti-PD1 therapy. Recently, 299 
Koyama et al. using two mouse models of lung adenocarcinoma, demonstrated that up-regulation of 300 
TIM3 on PD1+ lymphocytes was correlated with the induction of acquired resistance to anti-PD1 301 
therapy. Interestingly, it was shown that TIM3 expression was highest amongst T-cells with the 302 
greatest amount of PD1 bound. Given that anti-PD1 binding is limited by PD1 expression, this 303 
result would imply that in this model TIM3 was expressed upon severely exhausted PD1high CD8+ 304 
T-cells. Interestingly, T-cells from resistant tumors also over-expressed LAG3 and CTLA4, 305 
however, BTLA expression appeared variable [64]. The mechanisms that promote the induction of 306 
severe T-cell exhaustion within tumor microenvironments have not been completely characterized. 307 
Additionally, it is still not known whether reducing PD1 expression amongst severely exhausted, 308 
PD1high CD8+ T-cells would enhance sensitivity to anti-PD1/PDL1 therapies, or whether expression 309 
of receptors such as TIM3, BTLA, LAG3 can be independent of PD1. Further characterisation of 310 
exhausted T-cells in the context of anti-PD1/PDL1 resistance is therefore required.  311 
PD1-independent pathways 312 
Some tumors resistant to anti-PD1 therapy have been identified to simultaneously utilize 313 
multiple immunosuppressive pathways, indicating that in terms of function, additional pathways 314 
may compensate for the release of immune suppression provided by PD1 blockade. Metabolically 315 
limited by the local bioavailability of tryptophan, T-cells undergo proliferation arrest in its absence. 316 
Many tumors express the enzyme, indoleamine 2,3-dioxygenase (IDO) via the same IFN inducible 317 
  
mechanism as PDL1 [65]. Interestingly, expression of IDO by tumor cells has been demonstrated to 318 
render experimental mouse models of melanoma resistant to anti-PD1 therapy [66, 67]. While some 319 
metabolites are fundamentally necessary to facilitate T-cell activity, others behave in an inhibitory 320 
fashion. Under physiological conditions the production of pro-inflammatory stimuli such as cellular 321 
stress initiated by hypoxia or ischemia can promote the production of immunosuppressive 322 
adenosine. ATP released into the extracellular environment interacts with CD39, to produce AMP, 323 
which is further dephosphorylated by CD73 to adenosine. The ligation of adenosine with A2A 324 
receptors expressed by lymphocytes such as CD8+ T-cells inhibits their effector functions. Under 325 
physiological conditions, this pathway also prevents exaggerated tissue injury as a result of antigen-326 
specific immune responses [68]. The over-expression of CD73 in multiple cancer types has been 327 
associated with poor prognosis. Specifically, the absence of estrogen receptor expression has been 328 
inversely associated with high levels of CD73 expression, and also with metastatic potential [69, 329 
70]. In experimental mouse models of colon, prostate and breast cancers, Allard et al. demonstrated 330 
that activation of adenosine signalling enhanced the expression of PD1 on tumor-associated CD8+ 331 
T-cells, promoting a severely exhausted phenotype, and resistance to anti-PD1 therapy [71]. The 332 
functional significance of this pathway to PD1 inhibition remains to be characterized in humans, 333 
however, these preliminary studies provide compelling evidence supporting the notion that multiple 334 
independent immunosuppressive pathways within the tumor microenvironment can promote tumor 335 
development and resistance to anti-PD1 therapy. It is likely given the cellular heterogeneity of 336 
many tumors, that the activity of multiple immunosuppressive could function as both a primary and 337 
acquired resistance mechanism.  338 
In the context of anti-PD1 therapy, the direct subversion of T-cell-mediated effector 339 
functions appears to be a dominant feature amongst resistant tumors. The elevation of PD1 340 
expression level, co-expression of multiple inhibitory receptors, and production of 341 
immunosuppressive metabolites have each been demonstrated to affect the sensitivity of tumors to 342 
anti-PD1 therapy. The selection of tumor cells capable of limiting the exertion of T-cell-mediated 343 
  
anti-tumor immunity by promoting, an influx of Tregs, expression of PD1-independent inhibitory 344 
receptors, or production of immunosuppressive metabolites, could promote either primary or 345 
acquired resistance. Additionally, the heterogeneity present within most tumors might allow for the 346 
activity of multiple resistance pathways in tandem. The reinvigoration to T-cell effector functions 347 
provided by anti-PD1 therapy might lead to the selection of occult clones capable of subverting re-348 
invigorated immunosurveillance; their outgrowth and would likely herald the acquisition of 349 
resistance. 350 
 T-cell memory  351 
While effector CD8+ T-cells have been demonstrated to be necessary for the efficacy of anti-352 
PD1/PDL1 therapies, recent evidence suggests that the induction of T-cell memory is also an 353 
important consequence of sensitivity. Help by CD4+ T-cells, licenses DCs with the ability, not only 354 
to promote differentiation from a naïve to an effector CD8+ T-cell phenotype, but to also enable the 355 
eventual induction of CD8+ T-cell memory. This priming step induces rapid expansion and enables 356 
production of essential effector molecules [72].  Following the exertion of effector activity and 357 
antigen clearance, the contraction and resolution phase ensues. The small number of remaining cells 358 
enter into the memory phase where they can be maintained for the life of the host; capable of 359 
mounting rapid responses following antigen re-challenge [73]. Differences in their localisation, 360 
recall ability, and effector functions allow them to provide overlapping layers of protection against 361 
antigen re-encounter [74-77].  362 
Physiologically, activation and expansion of short lived CD4+ and CD8+ T-cells gives rise to 363 
a KLRG1hiCD127lo effector and KLRGloCD127hi memory precursor populations. Interestingly, 364 
chronic exposure to antigen can render the KLRGloCD127hi memory pre-cursors exhausted. Given 365 
that an endpoint of exhaustion can be deletion, this can have significant implications for memory 366 
cell development   [78]. Exhausted CD8+ T-cells become addicted to cognate antigen and depend on 367 
TCR signalling for survival [79]. Recently Ribas et al. who compared immune cell infiltrates within 368 
  
tumors pre- and post-treatment with anti-PD1 therapy, showed that CD8+ TEM were the major T-cell 369 
subset expanded in sensitive patients [80]. Specifically, patients categorised to have responded 370 
poorly to anti-PD1 therapy contained significantly fewer tumor-associated TEM than responsive 371 
patients. This result suggests two things; first, that induction of T-cells with an effector memory 372 
phenotype is a mechanism of action important to the efficacy of anti-PD1 therapy, and second, that 373 
resistance to anti-PD1 therapy limits memory T-cell induction [80].  Further exploration of 374 
resistance mechanisms active in non-responsive patients might allow for alternative therapeutic 375 
intervention and sensitisation.  376 
Progress of strategies to sensitize tumors to PD1 blockade.  377 
By summarising the current understanding of mechanisms contributing to the development 378 
of resistance to anti-PD1 therapy, we have highlighted several common targets for sensitising 379 
therapeutic intervention that may allow for effective combination therapeutic strategies to sensitise 380 
resistant patients. 381 
The role of immunosuppressive cell types within the tumor microenvironment has been well 382 
documented with respect to their ability to suppress anti-tumor immunity. Indeed, elevated Foxp3+ 383 
Tregs to CD8+ T-cell ratios are commonly associated with resistance to anti-PD1 therapy [59]. To 384 
reduce this ratio within the tumor microenvironment, a number of therapeutic strategies have 385 
demonstrated efficacy in targeting and depleting Tregs. The use of anti-CTLA4 therapy has been 386 
shown in several preclinical studies to deplete tumor-associated Tregs via an FcγR-dependant 387 
mechanism, and to also enhance the efficacy of tumor-specific T-cell-mediated anti-tumor 388 
immunity [81]. Given that the use of anti-CTLA4 in the clinic is associated with an increase in 389 
immune-related adverse events, it is possible that its mechanisms of action in humans involves 390 
depletion of Tregs, leading to a break down in peripheral tolerance [82]; its combination with anti-391 
PD1 therapy appears to be highly synergistic [22, 83]. Bulliard et al. demonstrated that tumor-392 
associated Tregs could be selectively depleted using anti-OX40 (CD134) mAbs, and that this 393 
  
resulted in growth reduction of tumors [84]. Encouragingly, the combination of anti-PD1 therapy 394 
with agonistic anti-OX40 mAbs has demonstrated synergistic anti-tumor efficacy in a model of 395 
ovarian cancer resistant to anti-PD1 therapy alone, and are currently being investigated within the 396 
clinic (ClinicalTrials.gov; NCT02205333 and NCT01303705) [85]. Additionally, TIM3 and T-cell 397 
Ig and ITIM domain (TIGIT) are commonly over-expressed by tumor-associated Tregs [86, 87]. 398 
Therapies which target and block the activity of either receptor have been shown to reduce Treg 399 
suppressive activity and to synergise with anti-PD1 therapy to enhance anti-tumor immunity in 400 
mouse models of colon cancer and melanoma, respectively [87, 88]. Anti-OX40, anti-TIM3 and 401 
anti-TIGIT therapies have not yet been trialed in combination with anti-PD1 therapy in the clinic. 402 
By contrast, clinical trials combining anti-CTLA4 and anti-PD1 therapy resulted in an objective 403 
response rate of 58% in patients with advanced melanoma; a significant improvement over single 404 
agent anti-CTLA4 therapy (19%) and numerically higher than anti-PD1 monotherapy (44%) [25]; 405 
representing a feasible method for alleviating Treg-mediated anti-PD1 therapeutic resistance.  406 
The poor immunogenicity of some tumors can limit the development of antigen-specific 407 
effector T-cells and consequently sensitivity to anti-PD1 therapy. Therapies that serve to liberate 408 
tumor antigen available for uptake by APCs are likely to enhance sensitivity to anti-PD1 therapy for 409 
patients with poorly immunogenic tumors [89-92]. Radio- and some chemo-therapeutic regimes can 410 
result in immunogenic cell death. Allowing for the release of tumor antigens, the use of such 411 
therapies in combination with anti-PD1/PDL1 mAbs might promote effective anti-tumor immunity 412 
[93, 94]. Both approaches have recently been proposed to synergise with checkpoint blockade by 413 
acting as a type of vaccination to prime adaptive immunity, while anti-PD1/PDL1 therapy amplifies 414 
anti-tumor immune responses by overcoming or preventing CD8+ T-cell exhaustion [93, 94]. 415 
Encouragingly, clinical trials combining radiotherapy (ClinicalTrials.gov; NCT02617589), or some 416 
chemotherapies such as doxorubicin – capable of inducing immunogenic cell death - 417 
(ClinicalTrials.gov; NCT02423954), with anti-PD1 therapy are currently underway [89-92]. Given 418 
that such regimes are commonly associated with severe side-effects, approaches that overcome 419 
  
these while offering their therapeutic benefit may prove more attractive. As such, autologous cancer 420 
vaccination strategies that prime adaptive immune responses with tumor-specific antigen have been 421 
demonstrated to improve sensitivity to anti-PD1 therapy [95]. As an alternative, neoantigen 422 
vaccination approaches have been demonstrated in mouse models to effectively increase tumor 423 
control. These studies have provided sufficient impetus to warrant investigation in humans. 424 
Neoantigen vaccination approaches have the benefit of being tumor-specific, however, they do run 425 
the risk of being diluted out by non-mutated peptide.  Rationally, the combination of such 426 
vaccination strategies with anti-PD1 therapy would likely serve two purposes: first, increasing the 427 
proportion of tumor-specific T-cells, and releasing them from tumor-induced immune suppression 428 
[32].  429 
An absence of lymphocyte enrichment within human melanomas has been associated with 430 
poor response to anti-PD1 therapy. Currently within the clinic, the combination of BRAF with 431 
MEK inhibitors (MEKi) have demonstrated considerable synergy in the treatment of metastatic 432 
BRAF mutant melanoma [96]. Having been demonstrated to require an intact immune system [97], 433 
this therapeutic combination has been shown to increase the proportion of CD8+, CD4+ and PD1+ 434 
lymphocytes within tumor tissue [98]. As such, the combination of BRAF/MEKi with anti-PD1 435 
therapy is currently under investigation within a clinical trial (ClinicalTrials.gov; NCT02130466) 436 
[99]. Alternative approaches for enhancing lymphocyte infiltration within tumor tissue have been 437 
investigated within pre-clinical models. Recently, as a means of promoting cytotoxic inflammatory 438 
responses within a mouse model of melanoma, Bald et al. demonstrated that peri-tumoral injections 439 
of immunostimulatory poly(I:C) RNA effectively promotes lymphocyte infiltration and impaired 440 
tumor growth. RNA-stimulated IFN-γ secretion was found to promote adaptive immune resistance 441 
within the tumor microenvironment by upregulating PDL1 expression. By combining 442 
immunostimulatory RNA with anti-PD1 therapy, anti-tumor immunity and tumor rejection were 443 
significantly improved. Such therapies, by promoting an IFNγ-rich environment might also serve to 444 
increase expression of class I MHC within many tumors, which is commonly down-regulated by 445 
  
tumors but required for T-cell-mediated anti-tumor responses. While effective in vivo, improved 446 
delivery mechanisms must be explored, as peri-tumoral injection into human metastases might 447 
prove anatomically limiting in some cases [100].  448 
The suppression placed upon APCs within the tumor microenvironment is largely supported 449 
by expression of cytokines such as VEGF and TGF-β. Encouragingly, the neutralisation of these 450 
cytokines using mAbs that bind and limit their bioavailability has been shown to liberate DC 451 
effector functions [101]. Indeed, therapeutic anti-VEGF mAbs (bevacizumab) are currently 452 
implemented within the clinic in combination with chemotherapeutic regimes to treat some cancers; 453 
its efficacy in combination with PD-1 blockade is currently being tested in clinical trial 454 
(ClinicalTrials.gov; NCT01454102). In cases where unknown suppressive factors within the 455 
microenvironment limit the activity of antigen presenting cells, stimulating effector functions may 456 
serve as method for improving anti-tumor immunity. Agonistic mAbs targeting the 457 
immunostimulatory molecules, CD40 or CD137 have also been shown to improve the effector 458 
functions of DCs. Approaches in which anti-PD1 mAbs have been combined with either anti-CD40 459 
or anti-CD137 mAbs have demonstrated considerable synergy in models of melanoma, breast and 460 
colon cancer [102, 103]. Additional approaches to enhance the activity of APCs within the tumor 461 
microenvironment include the use of oncolytic viruses. Talimogene laherparepvec (T-VEC) is a 462 
herpes simplex virus type 1-derived oncolytic immunotherapy designed to selectively replicate 463 
within tumors, to produce granulocyte macrophage colony-stimulating factor (GM-CSF) and to 464 
promote lytic tumor cell death. Tumor cell lysis combined with the chemotactic properties of GM-465 
CSF promotes the migration, antigen processing and maturation of DCs within the tumor 466 
microenvironment [104]. Indeed, intra-lesional T-VEC has demonstrated durable responses in 467 
highly selected patients with injectable metastases in phase III clinical trials of patients with 468 
melanoma [105]. Oncolytic viruses have also been demonstrated in vivo to prevent resistance to 469 
anti-PD1 therapy [106]. Indeed, T-VEC is currently being trialed in combination with anti-PD1 470 
therapy for patients with non-resectable melanoma, and in the phase 1 study of 21 patients with 471 
  
advanced melanoma, the combination was tolerable with a response rate of 57% 472 
(ClinicalTrials.gov; NCT02263508) [107]. While it is understood that cytolytic viruses can promote 473 
epitope spreading of tumor neoantigens [105], it is not clear what effect viral antigens have upon 474 
their efficacy. Importantly, therapies such as these are also limited by delivery methods. Currently, 475 
the efficacy of such therapies is dependent on local administration into tumor tissue [104]. 476 
Investigation of additional delivery methods that might allow for systemic administration and tumor 477 
specificity might improve its applicability for tumors in areas where local access is limited. 478 
Together, these studies demonstrate that antigen presentation can be improved within the tumor 479 
microenvironment. While trialed individually, therapeutic regimes combing anti-CD40 or anti-480 
CD137 with anti-PD1 mAbs, while likely to be effective, have not yet been trialed in humans. 481 
Current trials underway for combination anti-VEGF or viral therapies with anti-PD1 therapy 482 
represent a possible approach for enhancing antigen presentation within the tumor 483 
microenvironment and for enhancing sensitivity to anti-PD1 therapy within the not too distant 484 
future.  485 
Co-blockade of pathways, which in addition to PD1, promote T-cell exhaustion may 486 
overcome the resistance to anti-PD1 therapy. Encouragingly, therapeutic mAbs targeting either 487 
TIM3 or LAG3 in combination with PD1 have demonstrated synergistic outcomes in a variety of 488 
pre-clinical models. Indeed, the efficacy of anti-LAG3 with anti-PD1 is currently being investigated 489 
in a clinical trial for a number of solid tumors (ClinicalTrial.gov NCT01968109) [87, 108]. 490 
Additionally, blockade of immunosuppressive metabolites such as adenosine has also been 491 
investigated as a means to increase sensitivity to anti-PD1 therapy. Following the demonstration 492 
that inhibition of adenosine production within the tumor microenvironment could enhance the 493 
sensitivity of tumors to anti-PD1 and anti-CTLA4 mAb therapy in mouse models [71], clinical trials 494 
assessing the efficacy of anti-CD73 mAbs in cancer therapy have been initiated. Similarly, 495 
inhibition of A2A receptors in combination with anti-PD1 mAbs has also demonstrated synergistic 496 
anti-metastatic effects in pre-clinical models. We propose that the existence of clinically available 497 
  
A2A receptor inhibitors used in the treatment of Parkinson’s disease with a broad safety profile, 498 
might allow for rapid progression into clinical trials alongside anti-PD1 mAbs (NCT02655822: 499 
clinicaltrials.gov) [109]. A common problem associated with the use of antibodies with targets 500 
within the cellular milieu of tumors, is a lack of penetrance. IgG molecules are large and their 501 
distribution into tumor tissue can be limited by vasculature, stoma and cell density. To address this, 502 
high-affinity, soluble PD1 proteins have been developed to bind to and limit the association of 503 
PDL1 expressed within the tumor microenvironment with endogenously expressed PD1 on 504 
infiltrating lymphocytes [61]. Preliminary studies have demonstrated that the soluble PD1 protein is 505 
able to penetrate further into tissues than conventional therapeutic mAbs, that it avoids depletion of 506 
PDL1+ lymphocytes, and can increase anti-tumor immunity [110].  Therapies targeting T-cell 507 
immune suppression have collectively demonstrated high levels of efficacy. Indeed, mAb-based 508 
therapies against CD73, LAG3, TIM3 are all currently under investigation either alone or in 509 
combination with anti-PD1 therapy. A2A receptor inhibitors are already used within the clinic and 510 
given their broad safety spectrum could rationally be trailed in combination with anti-PD1 therapy. 511 
The ability to sensitise resistant tumors in which T-cell exhaustion or suppression are limiting 512 
factors might therefore be a realistic future therapeutic approach.  513 
Future directions 514 
To date, anti-cancer immunotherapies that target the PD1/PDL1 axis represent the most 515 
effective means of treatment for a variety of cancer types; they are well tolerated and can be used as 516 
monotherapies, but they are not perfect. Although a large proportion of patients treated with anti-517 
PD1 garner substantial benefits, most do not [3]. Here, we have proposed a model to explain how 518 
resistance to anti-PD1 therapy, as it is currently understood, is presented within a variety of tumors. 519 
Currently, the field of cancer immunotherapy is in its adolescence; it is almost certain that more will 520 
be learnt regarding mechanisms of resistance to anti-PD1 therapy as they are widely adopted within 521 
the clinic, however, the development of combination therapies aimed to sensitise patients may take 522 
much longer. Indeed, the vast majority of therapeutic combinations discussed here will require 523 
  
continuing research to identify optimal dosage and timing, and to demonstrate safety and efficacy 524 
when used in combination with anti-PD1/PDL1 therapies. If effective, these therapies will allow 525 
clinicians to tailor regimes in a patient-specific fashion, based not only upon tumor grade or 526 
biomarker status, but also upon the immunophenotype of the tumor itself. 527 
Until such therapies undergo late-stage large-scale trials it is unlikely that biomarkers to 528 
predict the efficacy of individual combination therapies will be identified. Importantly, tumor 529 
characteristics such as PDL1 expression and TIL abundance are not routinely examined. We 530 
recently discussed the strengths and limitations of a pragmatic framework to stratifying patients 531 
based upon PDL1 expression and TIL abundance in melanomas where such data has been gathered. 532 
This dictated that patients were divided into one of four groups; it accurately predicted that PDL1 533 
expression and TILs were predictive of response to anti-PD1 therapy in treatment of melanoma 534 
[27]. Given the importance of an immune permissive microenvironment to predict a long-term 535 
response, the immune contexture of pre-treatment biopsies might not accurately predict outcome. It 536 
might, therefore, be of benefit to also biopsy tumors under the influence of therapy to see whether it 537 
can, in itself influence immune infiltration. It is likely that as the mechanisms by which anti-PD1 538 
therapy functions and mechanisms of resistance are elucidated it is likely that more accurate 539 
stratification procedures may be developed; their implementation might inform clinicians as to 540 
which combination therapies might be applied to yield the greatest benefit for patients.  541 
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Figure Legends  799 
Figure 1 – Clinical response to anti-PD1/PDL1 therapies  800 
Patients can be stratified based upon response to anti-PD1/PDL1 therapies. Sensitivity is observed amongst 801 
~30% of melanoma patients treated and is characterised by stable disease progression or complete response; 802 
in combination with anti-CTLA4 therapy, this is further increased to ~50%. These are patients within whom 803 
adaptive immune resistance mechanisms function to subvert tumor-specific anti-tumor immune responses. 804 
By contrast, primary resistance is observed amongst 70% of patients and occurs within patients who garner 805 
no benefit from the outset of therapy. This is characterised as disease progression. Some patients who 806 
demonstrate encouraging initial responses to anti-PD1 therapy can eventually experience disease 807 
progression. These patients have acquired resistance.  808 
Figure 2 – Categories of resistance to anti-PD1 therapy 809 
In order for patients to demonstrate sensitivity to anti-PD1/PDL1 therapies a number of conditions must be 810 
met. A. Tumors must express antigens that differentiate them from their non-transformed counterparts, and 811 
to be permissive to antigen presenting cells (APCs) that are capable of gathering tumor antigen. B. APCs 812 
harbouring tumor antigen must undergo efficient migration and maturation; culminating in presentation to, 813 
and activation of, tumor antigen-specific T cells. C. Tumor-specific effector T cells must be capable of 814 
carrying out their effector functions in the presence of tumor antigen and unaffected by PD1-independent 815 
immunosuppressive factors within the tumor microenvironment. D. Tumors must display cognate antigen in 816 
order to be recognised, and also to express PDL1 – otherwise, it would be unlikely for PD1-mediated 817 
immune suppression to be active within the tumor microenvironment. E. In order to sustain anti-tumor 818 
immune responses long-term, induction of immunological memory must be preserved.  819 
 820 
Figure 3 – T cell exhaustion and resistance to anti-PD1/PDL1 therapies  821 
Exhaustion induced by PD1-independent pathways can induce resistance to anti-PD1/PDL1 therapies. A. 822 
Tumor-specific T cells that demonstrate a severe exhaustion phenotype, characterised by highly elevated 823 
PD1 expression have been demonstrated to be resistant to anti-PD1 therapies. B. The expression of 824 
  
exhaustion markers such as TIM3, LAG3 and CTLA4 might be capable of facilitating the induction of 825 
exhaustion via non-redundant pathways even in the presence of anti-PD1 therapy. C. The expression of 826 
immunosuppressive metabolites such as IDO or adenosine have been shown to suppress T cell effector 827 
functions even in the presence of anti-PD1 therapy.  828 
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 839 
Highlights: 840 
• Resistance to anti-PD1 therapy affects up to ~70% of patients treated.  841 
• Resistance can be primary or acquired.  842 
• Tumor intrinsic mechanisms that limit the induction of tumor-specific T cells or their 843 
efficacy within tumor tissue may promote resistance. 844 
• Logical therapeutic combinations might prove effective to prevent, or to treat resistant 845 
tumors.  846 
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